Whole transcriptome analysis of multiple Sclerosis patients reveals active inflammatory profile in relapsing patients and downregulation of neurological repair pathways in secondary progressive cases

被引:10
|
作者
Nali, Luiz H. [1 ,2 ]
Olival, Guilherme S. [3 ]
Sousa, Francielle T. G. [1 ]
de Oliveira, Ana Carolina S. [1 ]
Montenegro, Horacio [4 ]
da Silva, Israel T. [5 ]
Dias-Neto, Emamnuel [5 ,6 ]
Naya, Hugo [7 ]
Spangenberg, Lucia [7 ]
Penalva-de-Oliveira, Augusto C. [8 ]
Romano, Camila M. [1 ,9 ]
机构
[1] Univ Sao Paulo, Lab Virol, Inst Medicina Trop Sao Paulo, LIM52 LIMHC, Rua Dr Eneas de Carvalho Aguiar, BR-05403000 Sao Paulo, Brazil
[2] Univ Santo Amaro, Postgraduat Program Hlth Sci, Rua Prof Eneas Siqueira Neto 340, BR-04829300 Sao Paulo, Brazil
[3] Dept Neurol Santa Casa Misericordia Sao Paulo, R Dr Cesario Mota Jr 112, BR-01221020 Sao Paulo, Brazil
[4] ESALQ USP, Dept Zootecnia, BR-13400183 Piracicaba, SP, Brazil
[5] AC Camargo Canc Ctr, Lab Med Genom, BR-01525001 Sao Paulo, Brazil
[6] Univ Sao Paulo, Sao Paulo Med Sch, Inst Psychiat, Lab Neurosci LIM 27, Sao Paulo, Brazil
[7] Unidad Bioinformat Inst Pasteur Montevideo, Mataojo 2020, Montevideo 11400, Uruguay
[8] Inst Infectol Emilio Ribas, Dept Neurol, Ave Doutor Arnaldo 165, BR-01246900 Sao Paulo, Brazil
[9] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP LIM52, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
Multiple Sclerosis; Transcriptome; gene expression; RRMS; SPMS; NERVE GROWTH-FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENE-EXPRESSION; PEPTIDYLARGININE DEIMINASE-2; INDUCTION; TYPE-1; PAD2; RISK; NATALIZUMAB; CYTOKINES;
D O I
10.1016/j.msard.2020.102243
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Multiple sclerosis (MS) is an inflammatory autoimmune neurologic disease that causes progressive destruction of myelin sheath and axons. Affecting more than 2 million people worldwide, MS may presents distinct clinical courses. However, information regarding key gene expression and genic pathways related to each clinical form is still limited. Objective: To assess the whole transcriptome of blood leukocytes from patients with remittent-recurrent (RRMS) and secondary-progressive (SPMS) forms to explore the gene expression profile of each form. Methods: Total RNA was obtained and sequenced in Illumina HiSeq platform. Reads were aligned to human genome (GRCh38/hg38), BAM files were mapped and differential expression was obtained with DeSeq2. Up or downregulated pathways were obtained through Ingenuity IPA. Pro-inflammatory cytokines levels were also assessed. Results: The transcriptome was generated for nine patients (6 SPMS and 3 RRMS) and 5 healthy controls. A total of 731 and 435 differentially expressed genes were identified in SPMS and RRMS, respectively. RERE, IRS2, SIPA1L1, TANC2 and PLAGL1 were upregulated in both forms, whereas PAD2 and PAD4 were upregulated in RRMS and downregulated in SPMS. Inflammatory and neuronal repair pathways were upregulated in RRMS, which was also observed in cytokine analysis. Conversely, SPMS patients presented IL-8, IL-1, Neurothrophin and Neuregulin pathways down regulated. Conclusions: Overall, the transcriptome of RRMS and SPMS clearly indicated distinct inflammatory profiles, where RRMS presented marked pro-inflammatory profile but SPMS did not. SPMS individuals also presented a decrease on expression of neuronal repair pathways.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Mitoxantrone treatment in patients with relapsing remitting and secondary progressive multiple sclerosis
    Simu, M.
    Chirileanu, R. D.
    Reisz, D.
    Murariu, A.
    Lata, I.
    Suici, M.
    Bednar, M.
    Barsasteanu, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 288 - 288
  • [2] Intracortical excitability in patients with relapsing–remitting and secondary progressive multiple sclerosis
    A. Conte
    D. Lenzi
    V. Frasca
    F. Gilio
    E. Giacomelli
    M. Gabriele
    C. Marini Bettolo
    E. Iacovelli
    P. Pantano
    C. Pozzilli
    M. Inghilleri
    Journal of Neurology, 2009, 256 : 933 - 938
  • [3] Predictors of Conversion to Secondary Progressive Multiple Sclerosis in Patients with Relapsing-Remitting Multiple Sclerosis
    Kappos, L.
    Meier, D. P.
    Tomic, T.
    Haring, D.
    Bakshi, R.
    Meinert, R.
    Giovannoni, G.
    Chitnis, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 447 - 447
  • [4] Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis
    Esposito, Federica
    Radaelli, Marta
    Martinelli, Vittorio
    Sormani, Maria Pia
    Boneschi, Filippo Martinelli
    Moiola, Lucia
    Rocca, Maria Assunta
    Rodegher, Mariaemma
    Comi, Giancarlo
    MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (12) : 1490 - 1499
  • [5] Predictors of Conversion to Secondary Progressive Multiple Sclerosis in Patients With Relapsing-Remitting Multiple Sclerosis
    Tomic, Davorka
    Kappos, Ludwig
    Meier, Daniela Piani
    Haring, Dieter
    Meinert, Rolf
    Giovannoni, Gavin
    Chitnis, Tanuja
    NEUROLOGY, 2018, 90
  • [6] Intracortical excitability in patients with relapsing-remitting and secondary progressive multiple sclerosis
    Conte, A.
    Lenzi, D.
    Frasca, V.
    Gilio, F.
    Giacomelli, E.
    Gabriele, M.
    Bettolo, C. Marini
    Iacovelli, E.
    Pantano, P.
    Pozzilli, C.
    Inghilleri, M.
    JOURNAL OF NEUROLOGY, 2009, 256 (06) : 933 - 938
  • [7] NEDA as a predictor of conversion to secondary progressive multiple sclerosis in patients with relapsing-remitting multiple sclerosis
    Kappos, L.
    Stefano, N. D.
    Sormani, M. P.
    Giovannoni, G.
    Haring, D.
    Tomic, D.
    Meier, D. Piani
    Chitnis, T.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 638 - 639
  • [8] Interferon inducible transcriptional profile in secondary progressive multiple sclerosis patients
    Gurevich, M.
    Miron, G.
    Hanael, E.
    Sonis, P.
    Dolev, M.
    Magalashvili, D.
    Achiron, A.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 176 - 176
  • [9] Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis
    Hauser, Stephen L.
    Kappos, Ludwig
    Montalban, Xavier
    Guittari, Carol-Jean
    Koendgen, Harold
    Li, Carrie
    Marcillat, Carole
    Wormser, David
    Wolinsky, Jerry
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP13 - NP13
  • [10] Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis
    Hauser, S. L.
    Kappos, L.
    Montalban, X.
    Hughes, R.
    McNamara, J.
    Pradhan, A.
    Wormser, D.
    Koendgen, H.
    Wolinsky, J. S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 239 - 239